Zachariah DeFilipp1, Shuli Li2, Areej El-Jawahri1, Philippe Armand3, Lakshmi Nayak4, Nancy Wang5, Tracy T Batchelor5, Yi-Bin Chen1. 1. Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) is a therapeutic option for patients with primary central nervous system lymphoma (PCNSL). To the authors' knowledge, data are limited regarding its use among patients in first complete remission (CR1) with the CNS-directed conditioning regimen of thiotepa, busulfan, and cyclophosphamide (TBC). METHODS: A retrospective analysis of patients with PCNSL in CR1 who underwent transplantation using a TBC-based conditioning regimen at 2 academic institutions was performed. RESULTS: Forty-six consecutive patients who underwent HDC-ASCT while in CR1 were identified. The most common induction regimen was high-dose methotrexate plus temozolomide and rituximab (59%). No patients received whole-brain radiotherapy. A total of 40 patients (87%) received cytarabine before undergoing ASCT as either induction intensification, early consolidation therapy, or mobilization. The median time from diagnosis to transplantation was 6 months (range, 4-15 months). The median age of the patients at the time of transplantation was 59 years (range, 27-69 years). With a median follow-up of 2.7 years after ASCT (range, 6 months-7.5 years), the Kaplan-Meier estimates of 2-year overall survival and progression-free survival were 95% (95% confidence interval [95% CI], 80%-99%) and 92% (95% CI, 77%-97%), respectively. The most common toxicities were severe mucositis (35%) and bacterial infections occurring within 100 days of transplantation (35%). The estimated 2-year nonrecurrence mortality rate was 2.9% (95% CI, 0.2%-13.4%). CONCLUSIONS: HDC-ASCT with a CNS-directed conditioning regimen such as TBC should be considered for patients with PCNSL who are in CR1 because this approach is associated with encouraging disease control and survival in this select patient population. Cancer 2017;123:3073-79.
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) is a therapeutic option for patients with primary central nervous system lymphoma (PCNSL). To the authors' knowledge, data are limited regarding its use among patients in first complete remission (CR1) with the CNS-directed conditioning regimen of thiotepa, busulfan, and cyclophosphamide (TBC). METHODS: A retrospective analysis of patients with PCNSL in CR1 who underwent transplantation using a TBC-based conditioning regimen at 2 academic institutions was performed. RESULTS: Forty-six consecutive patients who underwent HDC-ASCT while in CR1 were identified. The most common induction regimen was high-dose methotrexate plus temozolomide and rituximab (59%). No patients received whole-brain radiotherapy. A total of 40 patients (87%) received cytarabine before undergoing ASCT as either induction intensification, early consolidation therapy, or mobilization. The median time from diagnosis to transplantation was 6 months (range, 4-15 months). The median age of the patients at the time of transplantation was 59 years (range, 27-69 years). With a median follow-up of 2.7 years after ASCT (range, 6 months-7.5 years), the Kaplan-Meier estimates of 2-year overall survival and progression-free survival were 95% (95% confidence interval [95% CI], 80%-99%) and 92% (95% CI, 77%-97%), respectively. The most common toxicities were severe mucositis (35%) and bacterial infections occurring within 100 days of transplantation (35%). The estimated 2-year nonrecurrence mortality rate was 2.9% (95% CI, 0.2%-13.4%). CONCLUSIONS: HDC-ASCT with a CNS-directed conditioning regimen such as TBC should be considered for patients with PCNSL who are in CR1 because this approach is associated with encouraging disease control and survival in this select patient population. Cancer 2017;123:3073-79.
Authors: Thomas Mika; Swetlana Ladigan; Alexander Baraniskin; Deepak Vangala; Sabine Seidel; Olaf Hopfer; Michael Kiehl; Roland Schroers Journal: Haematologica Date: 2019-08-08 Impact factor: 9.941
Authors: Lova Sun; Shuli Li; Areej El-Jawahri; Philippe Armand; Bimalangshu R Dey; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp Journal: Oncologist Date: 2017-12-28
Authors: Michael Scordo; Sejal M Morjaria; Eric R Littmann; Ankush Bhatia; Helen H Chung; Molly Maloy; Lisa M DeAngelis; Sergio A Giralt; Ying Taur; Craig S Sauter Journal: Biol Blood Marrow Transplant Date: 2018-04-18 Impact factor: 5.742
Authors: Matthew J Frigault; Jorg Dietrich; Kathleen Gallagher; Mark Roschewski; Justin T Jordan; Deborah Forst; Scott R Plotkin; Daniella Cook; Keagan S Casey; Kevin A Lindell; Gabriel D Depinho; Katelin Katsis; Eva Lynn Elder; Mark B Leick; Bryan Choi; Nora Horick; Frederic Preffer; Meredith Saylor; Steven McAfee; Paul V O'Donnell; Thomas R Spitzer; Bimalangshu Dey; Zachariah DeFilipp; Areej El-Jawahri; Tracy T Batchelor; Marcela V Maus; Yi-Bin Chen Journal: Blood Date: 2022-04-14 Impact factor: 25.476
Authors: Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter Journal: JAMA Oncol Date: 2021-07-01 Impact factor: 31.777
Authors: Niloufer Khan; Sarah Lindner; Antonio L C Gomes; Sean M Devlin; Gunjan L Shah; Anthony D Sung; Craig S Sauter; Heather J Landau; Parastoo B Dahi; Miguel-Angel Perales; David J Chung; Alexander M Lesokhin; Anqi Dai; Annelie Clurman; John B Slingerland; Ann E Slingerland; Daniel G Brereton; Paul A Giardina; Molly Maloy; Gabriel K Armijo; Carlos Rondon-Clavo; Emily Fontana; Lauren Bohannon; Sendhilnathan Ramalingam; Amy T Bush; Meagan V Lew; Julia A Messina; Eric Littmann; Ying Taur; Robert R Jenq; Nelson J Chao; Sergio Giralt; Kate A Markey; Eric G Pamer; Marcel R M van den Brink; Jonathan U Peled Journal: Blood Date: 2021-03-18 Impact factor: 25.476
Authors: Cui Chen; Peng Sun; Juan Cui; Shumei Yan; Hao Chen; Yi Xia; Xiwen Bi; Panpan Liu; Yu Wang; Hang Yang; Man Nie; Xue-Wen Zhang; Wenqi Jiang; Zhi-Ming Li Journal: Cancer Med Date: 2019-03-01 Impact factor: 4.452
Authors: Patricia A Young; Daria Gaut; Davis K Kimaiyo; Jonathan Grotts; Tahmineh Romero; John Chute; Gary Schiller; Sven de Vos; Herbert A Eradat; John Timmerman Journal: Clin Lymphoma Myeloma Leuk Date: 2020-02-20
Authors: Tommy Sheu; Sarah A Milgrom; Therese Y Andraos; Jillian R Gunther; Linda Chi; Loretta Nastoupil; Nathan Fowler; Yasuhiro Oki; Michelle A Fanale; Luis E Fayad; Fredrick Hagemeister; Sattva S Neelapu; L Jeffrey Medeiros; Chitra Hosing; Yago Nieto; Sairah Ahmed; Amin M Alousi; Bouthaina Dabaja; Chelsea C Pinnix Journal: Adv Radiat Oncol Date: 2018-07-12